Hi! I have a values of the mean per-base read coverage for each gene. My question what is it? How to calculate RPKM using these "the mean per-base read coverage". Thank you.
-
-
Can I use these values for the comparison of gene transcription between several distant samples? -
Going from a single number for each gene (which is what I presume you have in 'mean per-base read coverage') to something that encompasses all reads (the 'M' in RPKM) using the length of each gene (the 'K') seems hard if not impossible.
As for using the values for a comparison, normalizing them, making some broad assumptions and looking for gross changes, then I think that you could do so. I'd back up everything you find with other evidence but for a rough estimate of differential then your values will give you guidance.Comment
-
Thank you Rick. The "mean per-base read coverage" was computed on exons. So, if knowing gene length is it still hard to perform such a calculations?Comment
-
I suppose if you assume that all of your reads are the same length and if you know the lengths of your exons then you can determine the number of reads for each exon. From that information you can sum up the number of reads for all exons and sum up the lengths of all exons. From that information you can calculate RPKM for each exon. The assumption of all reads being the same length is the most critical part.Comment
-
Thank you very much. Say we have a gene of length 1000 bp and average read per-base equal to say 15. So what is the calculation procedure in numbers to deduct the RPKM?Comment
-
First, get the number of reads for each gene, call this number Rz . This would be Rz = L * A / X where:
L = length of the gene
A = average reads per base
X = length of a read
And lower-case 'z' represents the gene number (e.g., R1 is gene #1, R2 is gene #2, etc.)
Second, sum up the number of reads for all of the genes. Divide by 1,000,000. Call this number 'M'. In other words M = sum(Rz) / 1000000
Then for each gene you can determine the RPKM via Rz / L / MComment
-
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...10-14-2026, 09:55 AM -
Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.
We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing...
Comment